

Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference

Namodenoson, a Phase III cancer drug has strong potential in veterinary oncology, a market projected to reach [\\$3.1 billion](#) by 2030

Piclidenoson is currently in development for the treatment of osteoarthritis in pets; Clinical studies show efficacy in dogs, representing a [\\$3 billion](#) market

RAMAT GAN, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- [Can-Fite BioPharma Ltd.](#) (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today that it will participate in [BioFIT 2025](#), which will be held on December 2–3, 2025, in Strasbourg, France. BioFIT 2025 is a major European conference focused on life sciences, bringing together academia, industry, and investors to facilitate technology transfer, early-stage collaborations, and investment in biotech and medtech.

“Our previous participation at BioFIT led directly to our successful partnership with Vetbiolix for Piclidenoson for the treatment of osteoarthritis in dogs and cats, an agreement potentially worth an estimated \$325 million in royalty revenues for Can-Fite,” stated Dr. Sari Fishman, Can-Fite’s VP of Business Development. “As we return this year, we look forward to advancing new collaborations around Namodenoson and expanding our veterinary pipeline.”

At BioFIT 2025, Can-Fite aims to advance a second veterinary partnership focused on Namodenoson, its Phase III anti-cancer drug candidate. Namodenoson has demonstrated strong anti-tumor activity, complete response in human liver cancer patient and an excellent safety profile, making it a compelling candidate for veterinary oncology. In human clinical trials, Namodenoson is currently being evaluated in a Phase III liver cancer trial and Phase II pancreatic cancer study.

During the conference, Can-Fite will hold partnering meetings with major multinational animal health companies, including Elanco Animal Health and Zoetis, to explore collaboration opportunities for bringing Namodenoson into veterinary development.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for

the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: <https://www.canfite.com/>.

Forward-Looking Statements

This press release contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies, and potential revenue prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 7, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of

new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contact

Can-Fite BioPharma

Motti Farbstein

info@canfite.com

+972-3-9241114



Source: Can-Fite BioPharma Ltd.